Semiannual Report

Deutsche DWS Investments VIT Funds

DWS Equity 500 Index VIP



Contents

- 3 Performance Summary
- 4 Portfolio Summary
- 4 Portfolio Manager
- 5 Investment Portfolio
- 13 Statement of Assets and Liabilities
- **13** Statement of Operations
- **14** Statements of Changes in Net Assets
- 16 Financial Highlights
- **19** Notes to Financial Statements
- 25 Other Information
- 26 Information About Your Fund's Expenses
- 27 Liquidity Risk Management
- **27** Proxy Voting
- 28 Advisory Agreement Board Considerations and Fee Evaluation

This report must be preceded or accompanied by a prospectus. To obtain an additional prospectus or summary prospectus, if available, call (800) 728-3337 or your financial representative. We advise you to consider the Fund's objectives, risks, charges and expenses carefully before investing. The summary prospectus and prospectus contain this and other important information about the Fund. Please read the prospectus carefully before you invest.

Stocks may decline in value. Various factors, including costs, cash flows and security selection, may cause the Fund's performance to differ from that of the index. Investing in derivatives entails special risks relating to liquidity, leverage and credit that may reduce returns and/or increase volatility. The Fund may lend securities to approved institutions. Please read the prospectus for details.

War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises, natural disasters, climate change and related geopolitical events have led and, in the future, may lead to significant disruptions in U.S. and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the Fund and its investments.

The S&P 500® Index is a product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI"), and has been licensed for use by DWS Investment Management Americas, Inc. ("DIMA"). Standard & Poor's®, S&P® and S&P 500® are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by DIMA. The Fund is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product nor do they have any liability for any errors, omissions, or interruptions of the S&P 500 Index.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services.

DWS Distributors, Inc., 222 South Riverside Plaza, Chicago, IL 60606, (800) 621-1148

NOT FDIC/NCUA INSURED NO BANK GUARANTEE MAY LOSE VALUE NOT A DEPOSIT NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY

Performance Summary


June 30, 2023 (Unaudited)

Fund performance shown is historical, assumes reinvestment of all dividend and capital gain distributions, and does not guarantee future results. Investment return and principal value fluctuate with changing market conditions so that, when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. Please contact your participating insurance company for the Fund's most recent monthend performance. Performance figures for Classes A, B and B2 differ because each class maintains a distinct expense structure. Performance does not reflect charges and fees ("contract charges") associated with the separate account that invests in the Fund or any variable life insurance policy or variable annuity contract for which the Fund is an investment option. These charges and fees will reduce returns.

The gross expense ratios of the Fund, as stated in the fee table of each prospectus dated May 1, 2023 are 0.28%, 0.67% and 0.67% for Class A, Class B and Class B2 shares, respectively, and may differ from the expense ratios disclosed in the Financial Highlights tables in this report.

Generally accepted accounting principles require adjustments to be made to the net assets of the Fund at period end for financial reporting purposes only, and as such, the total return based on the unadjusted net asset value per share may differ from the total return reported in the financial highlights.

Growth of an Assumed \$10,000 Investment



S&P 500® Index is an unmanaged, capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries.

Index returns do not reflect any fees or expenses and it is not possible to invest directly into an index.

Comparative Results

DWS Equity 500 Ir	ndex VIP	6-Month [‡]	1-Year	3-Year	5-Year	10-Year
Class A	Growth of \$10,000	\$11,675	\$11,929	\$14,940	\$17,648	\$32,665
	Average annual total return	16.75%	19.29%	14.32%	12.03%	12.57%
S&P 500 Index	Growth of \$10,000	\$11,689	\$11,959	\$15,051	\$17,866	\$33,535
	Average annual total return	16.89%	19.59%	14.60%	12.31%	12.86%
DWS Equity 500 Ir	ndex VIP	6-Month‡	1-Year	3-Year	5-Year	10-Year
Class B	Growth of \$10,000	\$11,651	\$11,884	\$14,768	\$17,312	\$31,601
	Average annual total return	16.51%	18.84%	13.88%	11.60%	12.19%
S&P 500 Index	Growth of \$10,000	\$11,689	\$11,959	\$15,051	\$17,866	\$33,535
	Average annual total return	16.89%	19.59%	14.60%	12.31%	12.86%
DWS Equity 500 Ir	ndex VIP	6-Month‡	1-Year	3-Year	5-Year	10-Year
Class B2	Growth of \$10,000	\$11,653	\$11,885	\$14,764	\$17,301	\$31,428
	Average annual total return	16.53%	18.85%	13.87%	11.59%	12.13%
S&P 500 Index	Growth of \$10,000	\$11,689	\$11,959	\$15,051	\$17,866	\$33,535
	Average annual total return	16.89%	19.59%	14.60%	12.31%	12.86%

The growth of \$10,000 is cumulative.

[‡] Total returns shown for periods less than one year are not annualized.

Asset Allocation (As a % of Investment Portfolio excluding Securities Lending Collateral) 6/3	0/23	12/31/22
Common Stocks	99%	100%
Cash Equivalents	1%	0%
Government & Agency Obligations	0%	0%
1	00%	100%
Sector Diversification (As a % of Common Stocks) 6/3	0/23	12/31/22
Information Technology	28%	26%
Health Care	13%	16%
Financials	12%	12%
Consumer Discretionary	11%	10%
ndustrials	9%	8%
Communication Services	8%	7%
Consumer Staples	7%	7%
Energy	4%	5%
Utilities	3%	3%
Materials	3%	3%
	2%	3%
Real Estate		
11	00%	100%
Ten Largest Equity Holdings at June 30, 2023 (31.4% of Net Assets)		7.6%
1 Apple, Inc. Designs, manufactures and markets personal computers and related computing and mobile-communication device	3	7.6%
2 Microsoft Corp. Develops, manufactures, licenses, sells and supports software products		6.8%
3 Alphabet, Inc. Holding company with subsidiaries that provide web-based search, maps, hardware products and various software applications		3.5%
4 Amazon.com, Inc. Online retailer offering a wide range of products		3.1%
5 NVIDIA Corp. Designs, develops and markets three dimensional (3D) graphic processors		2.8%
6 Tesla, Inc. Designs, manufactures and sells high-perfomance electric vehicles and electric vehicle powertrain components		1.9%
7 Meta Platforms, Inc. Operator of social networking web site		1.7%
8 Berkshire Hathaway, Inc. Holding company of insurance business and a variety of other businesses		1.6%
9 UnitedHealth Group, Inc. Operator of organized health systems		1.2%

Portfolio holdings and characteristics are subject to change.

For more complete details about the Fund's investment portfolio, see page 5.

Following the Fund's fiscal first and third quarter-end, a complete portfolio holdings listing is posted on dws.com and is available free of charge by contacting your financial intermediary or, if you are a direct investor, by calling (800) 728-3337. In addition, the portfolio holdings listing is filed with the SEC on the Fund's Form N-PORT and will be available on the SEC's Web site at sec.gov. Additional portfolio holdings for the Fund are also posted on dws.com from time to time. Please see the Fund's current prospectus for more information.

Portfolio Manager

Brent Reeder

Senior Vice President, Northern Trust Investments, Inc., Subadvisor to the Fund

_	Shares	Value (\$)	_	Shares	Value (\$)
Common Stocks 99.1%			Broadline Retail 3.2%		
Communication Services 8	3.3%		Amazon.com, Inc.*	157,920	20,586,451
Diversified Telecommunication 5	Services 0.7%		eBay, Inc.	9,439	421,829
AT&T. Inc.	126,693	2,020,753	Etsy, Inc.*	2,196	185,804
Verizon Communications, Inc.	74,339	2,764,668			21,194,084
	,	4,785,421	Distributors 0.1%		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		4,705,421	Genuine Parts Co.	2,503	423,583
Entertainment 1.4%			LKQ Corp.	2,503 4,452	259,418
Activision Blizzard, Inc.*	12,636	1,065,215	Pool Corp.	4,452 688	259,416
Electronic Arts, Inc.	4,613	598,306	Fooi Corp.	000	
Live Nation Entertainment,	2 564	222 606			940,753
Inc.*	2,564	233,606	Hotels, Restaurants & Leisure 2.1	%	
Netflix, Inc.*	7,865	3,464,454	Booking Holdings, Inc.*	653	1,763,316
Take-Two Interactive Software, Inc.*	2,801	412,195	Caesars Entertainment, Inc.*	3,733	190,271
Walt Disney Co.*	32,313	2,884,905	Carnival Corp.*	17,392	327,491
Warner Bros Discovery, Inc.*	39,180	491,317	Chipotle Mexican Grill, Inc.*	491	1,050,249
vvariici bios biscovery, inc.	33,100	· · ·	Darden Restaurants, Inc.	2,142	357,885
		9,149,998	Domino's Pizza, Inc.	620	208,934
Interactive Media & Services 5.3	3%		Expedia Group, Inc.*	2,516	275,225
Alphabet, Inc. "A"*	105,123	12,583,223	Hilton Worldwide Holdings,		
Alphabet, Inc. "C"*	90,403	10,936,051	Inc.	4,682	681,465
Match Group, Inc.*	4,907	205,358	Las Vegas Sands Corp.*	5,828	338,024
Meta Platforms, Inc. "A"*	39,137	11,231,536	Marriott International, Inc. "A"	4,567	838,912
		34,956,168	McDonald's Corp.	12,911	3,852,772
Media 0.7%		, , , , , , , , , , , , , , , , , , , ,	MGM Resorts International	5,324	233,830
Charter Communications, Inc.			Norwegian Cruise Line	=	
"A"*	1,835	674,124	Holdings Ltd.*	7,483	162,905
Comcast Corp. "A"	73,581	3,057,291	Royal Caribbean Cruises Ltd.*	3,892	403,756
Fox Corp. "A"	4,767	162,078	Starbucks Corp.	20,270	2,007,946
Fox Corp. "B"	2,400	76,536	Wynn Resorts Ltd.	1,836	193,900
Interpublic Group of	2,100	70,000	Yum! Brands, Inc.	4,956	686,654
Companies, Inc.	6,780	261,572			13,573,535
News Corp. "A"	6,585	128,407	Household Durables 0.4%		
News Corp. "B"	2,250	44,370	D.R. Horton, Inc.	5,523	672,094
Omnicom Group, Inc.	3,532	336,070	Garmin Ltd.	2,690	280,540
Paramount Global "B"	9,072	144,336	Lennar Corp. "A"	4,465	559,509
		4,884,784	Mohawk Industries, Inc.*	953	98,312
\\/:		1,001,701	Newell Brands, Inc.	6,800	59,160
Wireless Telecommunication Se		4 444 557	NVR, Inc.*	54	342,934
T-Mobile U.S., Inc.*	10,184	1,414,557	PulteGroup, Inc.	3,981	309,244
Consumer Discretionary 10	0.6%		Whirlpool Corp.	955	142,094
Automobile Components 0.1%					2,463,887
Aptiv PLC*	4,849	495,034			2,403,007
BorgWarner, Inc.	4,092	200,140	Leisure Products 0.0%		
_		695,174	Hasbro, Inc.	2,360	152,857
A		000,174	Specialty Retail 2.1%		
Automobiles 2.2%	00.400	1.050.040	Advance Auto Parts, Inc.	1,060	74,518
Ford Motor Co.	69,439	1,050,612	AutoZone, Inc.*	325	810,342
General Motors Co.	24,658	950,812	Bath & Body Works, Inc.	4,043	151,612
Tesla, Inc.*	47,658	12,475,435	Best Buy Co., Inc.	3,513	287,890
		14,476,859	CarMax, Inc.*	2,793	233,774
			Home Depot, Inc.	17,914	5,564,805
			Lowe's Companies, Inc.	10,549	2,380,909

_	Shares	Value (\$)		Shares	Value (\$)
O'Reilly Automotive, Inc.*	1,076	1,027,903	Clorox Co.	2,178	346,389
Ross Stores, Inc.	6,083	682,087	Colgate-Palmolive Co.	14,621	1,126,402
TJX Companies, Inc.	20,349	1,725,392	Kimberly-Clark Corp.	5,984	826,151
Tractor Supply Co.	1,928	426,281	Procter & Gamble Co.	41,685	6,325,282
Ulta Beauty, Inc.*	884	416,006			9,056,817
	•	13,781,519	Personal Care Products 0.1%		0,000,011
Textiles, Apparel & Luxury Good	s 0 1%	,,	Estee Lauder Companies,		
NIKE, Inc. "B"	21,778	2,403,638	Inc. "A"	4.112	807,514
Ralph Lauren Corp.	715	88,159	Tobacco 0.6%	.,	221,211
Tapestry, Inc.	4,125	176,550	Altria Group, Inc.	31,568	1,430,031
VF Corp.	6,006	114,655	Philip Morris International,	31,000	1,430,031
VI Corp.	0,000	· · ·	Inc.	27,452	2,679,864
		2,783,002		27,102	4,109,895
Consumer Staples 6.6%			En aver 4 19/		4,103,033
Beverages 1.7%			Energy 4.1%		
Brown-Forman Corp. "B"	3,293	219,906	Energy Equipment & Services 0.4%		
Coca-Cola Co.	68,810	4,143,738	Baker Hughes Co.	17,903	565,914
Constellation Brands, Inc. "A"	2,866	705,408	Halliburton Co.	15,943	525,959
Keurig Dr Pepper, Inc.	14,832	463,797	Schlumberger NV	25,115	1,233,649
Molson Coors Beverage Co.					2,325,522
"B"	3,352	220,696	Oil, Gas & Consumable Fuels 3.7%		
Monster Beverage Corp.*	13,506	775,785	APA Corp.	5,443	185,987
PepsiCo, Inc.	24,372	4,514,182	Chevron Corp.	30,829	4,850,943
		11,043,512	ConocoPhillips	21,419	2,219,223
Consumer Staples Distribution 8	& Retail 1.8%		Coterra Energy, Inc.	13,375	338,387
Costco Wholesale Corp.	7,844	4,223,053	Devon Energy Corp.	11,334	547,886
Dollar General Corp.	3,871	657,218	Diamondback Energy, Inc.	3,196	419,827
Dollar Tree, Inc.*	3,674	527,219	EOG Resources, Inc.	10,345	1,183,882
Kroger Co.	11,512	541,064	EQT Corp.	6,402	263,314
Sysco Corp.	8,921	661,938	Exxon Mobil Corp.	71,538	7,672,450
Target Corp.	8,170	1,077,623	Hess Corp.	4,915	668,194
Walgreens Boots Alliance,			Kinder Morgan, Inc.	34,794	599,153
Inc.	12,837	365,726	Marathon Oil Corp.	10,908	251,102
Walmart, Inc.	24,810	3,899,636	Marathon Petroleum Corp.	7,510	875,666
		11,953,477	Occidental Petroleum Corp.	12,714	747,583
Food Products 1.0%			ONEOK, Inc.	7,986	492,896
Archer-Daniels-Midland Co.	9,701	733,008	Phillips 66	8,122	774,676
Bunge Ltd.	2,633	248,424	Pioneer Natural Resources		
Campbell Soup Co.	3,586	163,916	Co.	4,132	856,068
Conagra Brands, Inc.	8,538	287,901	Targa Resources Corp.	3,971	302,193
General Mills, Inc.	10,371	795,456	Valero Energy Corp.	6,396	750,251
Hormel Foods Corp.	5,150	207,133	Williams Companies, Inc.	21,477	700,795
Kellogg Co.	4,619	311,321			24,700,476
Kraft Heinz Co.	14,133	501,721	Financials 12.3%		
Lamb Weston Holdings, Inc.	2,524	290,134	Banks 3.0%		
McCormick & Co., Inc.	4,441	387,388	Bank of America Corp.	122,671	3,519,431
Mondelez International, Inc.			Citigroup, Inc.	34,378	1,582,763
"A"	24,062	1,755,082	Citizens Financial Group, Inc.	8,495	221,549
The Hershey Co.	2,611	651,967	Comerica, Inc.	2,308	97,767
The J.M. Smucker Co.	1,873	276,586	Fifth Third Bancorp.	11,886	311,532
Tyson Foods, Inc. "A"	5,087	259,640	Huntington Bancshares, Inc.	25,787	277,984
		6,869,677	JPMorgan Chase & Co.	51,706	7,520,121
Household Products 1.4%			KeyCorp.	16,565	153,061
Church & Dwight Co., Inc.	4,316	432,593	M&T Bank Corp.	2,964	366,825
- · ·	*	-	•	•	*

_	Shares	Value (\$)	_	Shares	Value (\$)
PNC Financial Services	7.047	007.570	Insurance 2.0%		
Group, Inc.	7,047	887,570	Aflac, Inc.	9,723	678,665
Regions Financial Corp.	16,534	294,636	Allstate Corp.	4,644	506,382
Truist Financial Corp.	23,396	710,068	American International Group,		
U.S. Bancorp.	24,550	811,132	Inc.	12,795	736,224
Wells Fargo & Co.	66,403	2,834,080	Aon PLC "A"	3,609	1,245,827
Zions Bancorp. NA	2,813	75,557	Arch Capital Group Ltd.*	6,589	493,187
		19,664,076	Arthur J. Gallagher & Co.	3,770	827,779
Capital Markets 2.6%			Assurant, Inc.	925	116,291
Ameriprise Financial, Inc.	1,843	612,171	Brown & Brown, Inc.	4,166	286,787
Bank of New York Mellon	.,0.0	0.2,	Chubb Ltd.	7,309	1,407,421
Corp.	12,683	564,647	Cincinnati Financial Corp.	2,773	269,868
BlackRock, Inc.	2,648	1,830,139	Everest Re Group Ltd.	762	260,497
Cboe Global Markets, Inc.	1,884	260,011	Globe Life, Inc.	1,553	170,240
Charles Schwab Corp.	26,285	1,489,834	Hartford Financial Services		
CME Group, Inc.	6,387	1,183,447	Group, Inc.	5,517	397,334
FactSet Research Systems,	0,007	.,,	Lincoln National Corp.	2,884	74,292
Inc.	688	275,647	Loews Corp.	3,303	196,132
Franklin Resources, Inc.	5,014	133,924	Marsh & McLennan		
Intercontinental Exchange,	•	,	Companies, Inc.	8,742	1,644,195
Inc.	9,927	1,122,545	MetLife, Inc.	11,368	642,633
Invesco Ltd.	8,046	135,253	Principal Financial Group, Inc.	3,987	302,374
MarketAxess Holdings, Inc.	668	174,628	Progressive Corp.	10,394	1,375,854
Moody's Corp.	2,793	971,182	Prudential Financial, Inc.	6,434	567,608
Morgan Stanley	23,049	1,968,385	Travelers Companies, Inc.	4,094	710,964
MSCI, Inc.	1,416	664,515	W.R. Berkley Corp.	3,627	216,024
Nasdag, Inc.	6,096	303,886	Willis Towers Watson PLC	1,911	450,041
Northern Trust Corp.	3,736	276,987		-	40.550.040
Northern hust corp.	3,730	270,307			13 5/6 619
•	3,730	270,307	11141. 040.00/		13,576,619
Raymond James Financial, Inc.	3,368	349,497	Health Care 13.3%		13,576,619
Raymond James Financial,			Health Care 13.3% Biotechnology 1.9%		13,576,619
Raymond James Financial, Inc.	3,368	349,497		31,203	4,203,980
Raymond James Financial, Inc. S&P Global, Inc.	3,368 5,800	349,497 2,325,162	Biotechnology 1.9%	31,203 9,447	
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp.	3,368 5,800 5,905	349,497 2,325,162 432,128	Biotechnology 1.9% AbbVie, Inc.		4,203,980
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc.	3,368 5,800 5,905	349,497 2,325,162 432,128	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc.	9,447	4,203,980 2,097,423
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group,	3,368 5,800 5,905 3,952	349,497 2,325,162 432,128 442,703 1,897,503	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.*	9,447 2,559	4,203,980 2,097,423 728,931
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc.	3,368 5,800 5,905 3,952	349,497 2,325,162 432,128 442,703	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc.	9,447 2,559 22,149	4,203,980 2,097,423 728,931 1,707,024
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5%	3,368 5,800 5,905 3,952 5,883	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.*	9,447 2,559 22,149 3,300	4,203,980 2,097,423 728,931 1,707,024 205,425
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co.	3,368 5,800 5,905 3,952 5,883	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.*	9,447 2,559 22,149 3,300	4,203,980 2,097,423 728,931 1,707,024 205,425
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp.	3,368 5,800 5,905 3,952 5,883	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals,	9,447 2,559 22,149 3,300 5,797	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.*	9,447 2,559 22,149 3,300 5,797	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp.	3,368 5,800 5,905 3,952 5,883	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supplement	9,447 2,559 22,149 3,300 5,797 1,910 4,553	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories	9,447 2,559 22,149 3,300 5,797 1,910 4,553	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc.	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co.	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc.	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCorTechnologies, Inc.*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611 - 31,554 10,483 10,917 1,300	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Suppl Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCor Technologies, Inc.* Global Payments, Inc.	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611 - 31,554 10,483 10,917 1,300 4,630	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Suppl Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCorTechnologies, Inc.*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611 - 31,554 10,483 10,917 1,300	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404 456,148	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.* GE HealthCare Technologies,	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858 10,708	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322 1,010,086
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCor Technologies, Inc.* Global Payments, Inc. Jack Henry & Associates, Inc. Mastercard, Inc. "A"	3,368 5,800 5,905 3,952 5,883 	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404 456,148 218,533 5,821,627	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Suppl Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.* GE HealthCare Technologies, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858 10,708 6,917	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322 1,010,086 561,937
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCor Technologies, Inc.* Global Payments, Inc. Jack Henry & Associates, Inc. Mastercard, Inc. "A" PayPal Holdings, Inc.*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611 31,554 10,483 10,917 1,300 4,630 1,306 14,802 19,723	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404 456,148 218,533 5,821,627 1,316,116	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.* GE HealthCare Technologies, Inc.* Hologic, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858 10,708 6,917 4,339	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322 1,010,086 561,937 351,329
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCor Technologies, Inc.* Global Payments, Inc. Jack Henry & Associates, Inc. Mastercard, Inc. "A"	3,368 5,800 5,905 3,952 5,883 	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404 456,148 218,533 5,821,627 1,316,116 6,798,102	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Suppl Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.* GE HealthCare Technologies, Inc.* Hologic, Inc.* IDEXX Laboratories, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858 10,708 6,917 4,339 1,467	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322 1,010,086 561,937 351,329 736,771
Raymond James Financial, Inc. S&P Global, Inc. State Street Corp. T. Rowe Price Group, Inc. The Goldman Sachs Group, Inc. Consumer Finance 0.5% American Express Co. Capital One Financial Corp. Discover Financial Services Synchrony Financial Financial Services 4.2% Berkshire Hathaway, Inc. "B"* Fidelity National Information Services, Inc. Fiserv, Inc.* FleetCor Technologies, Inc.* Global Payments, Inc. Jack Henry & Associates, Inc. Mastercard, Inc. "A" PayPal Holdings, Inc.*	3,368 5,800 5,905 3,952 5,883 10,520 6,717 4,496 7,611 31,554 10,483 10,917 1,300 4,630 1,306 14,802 19,723	349,497 2,325,162 432,128 442,703 1,897,503 17,414,194 1,832,584 734,638 525,358 258,165 3,350,745 10,759,914 573,420 1,377,179 326,404 456,148 218,533 5,821,627 1,316,116	Biotechnology 1.9% AbbVie, Inc. Amgen, Inc. Biogen, Inc.* Gilead Sciences, Inc. Incyte Corp.* Moderna, Inc.* Regeneron Pharmaceuticals, Inc.* Vertex Pharmaceuticals, Inc.* Health Care Equipment & Supple Abbott Laboratories Align Technology, Inc.* Baxter International, Inc. Becton, Dickinson & Co. Boston Scientific Corp.* DENTSPLY SIRONA, Inc. DexCom, Inc.* Edwards Lifesciences Corp.* GE HealthCare Technologies, Inc.* Hologic, Inc.*	9,447 2,559 22,149 3,300 5,797 1,910 4,553 lies 2.9% 30,743 1,257 9,065 5,032 25,399 3,844 6,858 10,708 6,917 4,339	4,203,980 2,097,423 728,931 1,707,024 205,425 704,336 1,372,411 1,602,246 12,621,776 3,351,602 444,525 413,001 1,328,498 1,373,832 153,837 881,322 1,010,086 561,937 351,329

_	Shares	Value (\$)	_	Shares	Value (\$)
Medtronic PLC	23,526	2,072,641	Viatris, Inc.	21,497	214,540
ResMed, Inc.	2,591	566,134	Zoetis, Inc.	8,163	1,405,750
STERIS PLC	1,775	399,340			27,215,815
Stryker Corp.	5,984	1,825,659	l		27,213,013
Teleflex, Inc.	846	204,757	Industrials 8.4%		
The Cooper Companies, Inc.	880	337,418	Aerospace & Defense 1.6%		
Zimmer Biomet Holdings, Inc.	3,673	534,789	Axon Enterprise, Inc.*	1,217	237,461
	-	19,026,670	Boeing Co.*	9,995	2,110,544
Health Care Providers & Service	2 00/	10,020,010	General Dynamics Corp.	4,005	861,676
		EE1 100	Howmet Aerospace, Inc.	6,511	322,685
AmerisourceBergen Corp. Cardinal Health, Inc.	2,864 4,501	551,120	Huntington Ingalls Industries,	705	100 450
Centene Corp.*	9,729	425,660 656,221	Inc.	705	160,458
Cigna Group	5,230	1,467,538	L3Harris Technologies, Inc.	3,367	659,158
CVS Health Corp.	22,679	1,567,799	Lockheed Martin Corp.	3,990	1,836,916
DaVita, Inc.*	936	94,040	Northrop Grumman Corp.	2,526	1,151,351
Elevance Health, Inc.	4,188	1,860,686	Raytheon Technologies Corp. Textron, Inc.	25,865 3,546	2,533,735 239,816
HCA Healthcare, Inc.	3,651	1,108,005	TransDigm Group, Inc.	3,540 917	819,954
Henry Schein, Inc.*	2,296	186,206	nansbigin Group, inc.	917	
Humana, Inc.	2,220	992,629			10,933,754
Laboratory Corp. of America	2,220	002,020	Air Freight & Logistics 0.6%		
Holdings	1,563	377,199	C.H. Robinson Worldwide,		
McKesson Corp.	2,401	1,025,971	Inc.	2,045	192,946
Molina Healthcare, Inc.*	1,046	315,097	Expeditors International of	2,692	326,082
Quest Diagnostics, Inc.	1,947	273,670	Washington, Inc. FedEx Corp.	4,089	1,013,663
UnitedHealth Group, Inc.	16,464	7,913,257	United Parcel Service, Inc. "B"	12,816	2,297,268
Universal Health Services,			Officed Farcer Service, Inc. B	12,010	
Inc. "B"	1,111	175,282			3,829,959
		18,990,380	Building Products 0.4%		
Life Sciences Tools & Services 1	.6%		A.O. Smith Corp.	2,295	167,030
Agilent Technologies, Inc.	5,240	630,110	Allegion PLC	1,610	193,232
Bio-Rad Laboratories, Inc.			Carrier Global Corp.	14,747	733,074
"A"*	374	141,791	Johnson Controls	10 174	000 500
Bio-Techne Corp.	2,811	229,462	International PLC Masco Corp.	12,174 3,960	829,536 227,225
Charles River Laboratories			Trane Technologies PLC	4,054	
International, Inc.*	933	196,163	Traffe recritologies FLC	4,054	775,368
Danaher Corp.	11,745	2,818,800			2,925,465
Illumina, Inc.*	2,778	520,847	Commercial Services & Supplies	6 0.5%	
IQVIA Holdings, Inc.* Mettler-Toledo International,	3,282	737,695	Cintas Corp.	1,532	761,526
Inc.*	389	510,228	Copart, Inc.*	7,584	691,737
Revvity, Inc.	2,202	261,576	Republic Services, Inc.	3,680	563,666
Thermo Fisher Scientific, Inc.	6,822	3,559,378	Rollins, Inc.	4,153	177,873
Waters Corp.*	1,059	282,266	Waste Management, Inc.	6,540	1,134,167
West Pharmaceutical	,	,			3,328,969
Services, Inc.	1,311	501,418	Construction & Engineering 0.1%	6	
		10,389,734	Quanta Services, Inc.	2,560	502,912
Pharmaceuticals 4.1%			Electrical Equipment 0.6%		
Bristol-Myers Squibb Co.	37,126	2,374,208	AMETEK, Inc.	4,106	664,679
Catalent, Inc.*	3,163	137,148	Eaton Corp. PLC	7,060	1,419,766
Eli Lilly & Co.	13,940	6,537,581	Emerson Electric Co.	10,117	914,476
Johnson & Johnson	45,962	7,607,630	Generac Holdings, Inc.*	1,102	164,341
Merck & Co., Inc.	44,878	5,178,473	Rockwell Automation, Inc.	2,026	667,466
Organon & Co.	4,721	98,244	,	2,020	
Pfizer, Inc.	99,843	3,662,241			3,830,728
·	/	,			

	Shares	Value (\$)	_	Shares	Value (\$)
Ground Transportation 0.8%			Robert Half International, Inc.	1,913	143,896
CSX Corp.	35,885	1,223,678	Verisk Analytics, Inc.	2,559	578,411
J.B. Hunt Transport Services,		.,==,,		_	4,760,507
Inc.	1,490	269,735	Trading Companies & Distributors	s 0 3%	
Norfolk Southern Corp.	4,031	914,070	Fastenal Co.	10,086	594,973
Old Dominion Freight Line,	4 500	F00 000	United Rentals, Inc.	1,214	540,679
Inc.	1,598	590,860	W.W. Grainger, Inc.	789	622,198
Union Pacific Corp.	10,776	2,204,985	G ,	_	1,757,850
		5,203,328	Information Technology 28.0	0/	1,737,030
Industrial Conglomerates 0.8%			· · ·		
3M Co.	9,754	976,278	Communications Equipment 0.9%		
General Electric Co.	19,265	2,116,260	Arista Networks, Inc.*	4,419	716,143
Honeywell International, Inc.	11,760	2,440,200	Cisco Systems, Inc.	72,513	3,751,823
		5,532,738	F5, Inc.*	1,033	151,087
Machinery 1.8%			Juniper Networks, Inc.	5,797	181,620
Caterpillar, Inc.	9,116	2,242,992	Motorola Solutions, Inc.	2,969	870,748
Cummins, Inc.	2,494	611,429			5,671,421
Deere & Co.	4,769	1,932,351	Electronic Equipment, Instrumen	ts &	
Dover Corp.	2,478	365,876	Components 0.6%		
Fortive Corp.	6,308	471,649	Amphenol Corp. "A"	10,486	890,786
IDEX Corp.	1,319	283,928	CDW Corp.	2,419	443,887
Illinois Tool Works, Inc.	4,882	1,221,281	Corning, Inc.	13,682	479,417
Ingersoll Rand, Inc.	7,148	467,193	Keysight Technologies, Inc.*	3,149	527,300
Nordson Corp.	938	232,793	TE Connectivity Ltd.	5,539 825	776,346
Otis Worldwide Corp.	7,328	652,265	Teledyne Technologies, Inc.* Trimble, Inc.*	825 4,449	339,166
PACCAR, Inc.	9,251	773,846	Zebra Technologies Corp. "A"*	4,449 899	235,530 265,951
Parker-Hannifin Corp.	2,269	885,001	Zebra recritiologies Corp. A	099 _	
Pentair PLC	2,958	191,087			3,958,383
Snap-on, Inc.	930	268,017	IT Services 1.1%		
Stanley Black & Decker, Inc.	2,690	252,080	Accenture PLC "A"	11,188	3,452,393
Westinghouse Air Brake Technologies Corp.	3,185	349,299	Akamai Technologies, Inc.*	2,686	241,391
Xylem, Inc.	4,245	478,072	Cognizant Technology	0.000	F07 740
Ayloni, mo.	1,2 10	11,679,159	Solutions Corp. "A"	9,003	587,716 106,185
		11,079,159	DXC Technology Co.* EPAM Systems, Inc.*	3,974 1,030	,
Passenger Airlines 0.2%			Gartner, Inc.*	1,030	231,493 489,733
Alaska Air Group, Inc.*	2,169	115,347	International Business	1,390	409,733
American Airlines Group, Inc.*	11,533	206,902	Machines Corp.	16,056	2,148,453
Delta Air Lines, Inc.*	11,471	545,331	VeriSign, Inc.*	1,599	361,326
Southwest Airlines Co.	10,356	374,991		_	7,618,690
United Airlines Holdings, Inc.*	5,834	320,112	Coming durateur 8 Coming durate		7,010,000
g-,g-,g-,	-	1,562,683	Semiconductors & Semiconductors Equipment 7.3%	or	
D 6 1 10 1 0 70/		1,302,003	Advanced Micro Devices,		
Professional Services 0.7% Automatic Data Processing,			Inc.*	28,489	3,245,182
Inc.	7,305	1,605,566	Analog Devices, Inc.	8,945	1,742,576
Broadridge Financial	7,000	1,000,000	Applied Materials, Inc.	14,957	2,161,885
Solutions, Inc.	2,101	347,989	Broadcom, Inc.	7,377	6,399,031
Ceridian HCM Holding, Inc.*	2,730	182,828	Enphase Energy, Inc.*	2,412	403,962
Equifax, Inc.	2,167	509,895	First Solar, Inc.*	1,762	334,939
Jacobs Solutions, Inc.	2,221	264,055	Intel Corp.	73,776	2,467,069
Leidos Holdings, Inc.	2,463	217,926	KLA Corp.	2,429	1,178,114
Paychex, Inc.	5,673	634,638	Lam Research Corp.	2,377	1,528,078
Paycom Software, Inc.	857	275,303	Microchip Technology, Inc.	9,693	868,396
			Micron Technology, Inc.	19,387	1,223,514

_	Shares	Value (\$)		Shares	Value (\$)
Monolithic Power Systems, Inc.	792	427,862	FMC Corp. International Flavors &	2,245	234,243
NVIDIA Corp.	43,755	18,509,240	Fragrances, Inc.	4,578	364,363
NXP Semiconductors NV	4,584	938,253	Linde PLC	8,655	3,298,247
ON Semiconductor Corp.*	7,631	721,740	LyondellBasell Industries NV	2,000	-,,
Qorvo, Inc.*	1,747	178,246	"A"	4,461	409,654
QUALCOMM, Inc.	19,705	2,345,683	PPG Industries, Inc.	4,154	616,038
Skyworks Solutions, Inc.	2,794	309,268	Sherwin-Williams Co.	4,146	1,100,846
SolarEdge Technologies, Inc.*	1,003	269,857	The Mosaic Co.	5,855	204,925
Teradyne, Inc.	2,734	304,376			11,273,933
Texas Instruments, Inc.	16,057	2,890,581	Construction Materials 0.2%		
		48,447,852	Martin Marietta Materials, Inc.	1,095	505,550
Software 10.2%		10,117,002	Vulcan Materials Co.	2,347	529,108
Adobe, Inc.*	8,115	3,968,154			1,034,658
ANSYS, Inc.*	1,532	505,974	Containers & Packaging 0.2%		
Autodesk, Inc.*	3,785	774,449	Amcor PLC	25,717	256,656
Cadence Design Systems,			Avery Dennison Corp.	1,463	251,343
Inc.*	4,826	1,131,793	Ball Corp.	5,536	322,250
Fair Isaac Corp.*	446	360,908	International Paper Co.	6,257	199,035
Fortinet, Inc.*	11,506	869,739	Packaging Corp. of America	1,637	216,346
Gen Digital, Inc.	10,102	187,392	Sealed Air Corp.	2,482	99,280
Intuit, Inc.	4,959	2,272,164	Westrock Co.	4,438	129,013
Microsoft Corp.	131,550	44,798,037		.,	1,473,923
Oracle Corp.	27,237	3,243,654			1,473,323
Palo Alto Networks, Inc.*	5,354	1,368,000	Metals & Mining 0.4%		
PTC, Inc.*	1,900	270,370	Freeport-McMoRan, Inc.	25,359	1,014,360
Roper Technologies, Inc.	1,882	904,866	Newmont Corp.	14,065	600,013
Salesforce, Inc.*	17,319	3,658,812	Nucor Corp.	4,414	723,808
ServiceNow, Inc.*	3,602	2,024,216	Steel Dynamics, Inc.	2,901	316,006
Synopsys, Inc.*	2,704 739	1,177,349			2,654,187
Tyler Technologies, Inc.*	739	307,771	Real Estate 2.5%		
		67,823,648	Health Care REITs 0.2%		
Technology Hardware, Storage &	L		Healthpeak Properties, Inc.	9,588	192,719
Peripherals 7.9%			Ventas, Inc.	7,071	334,246
Apple, Inc.	261,570	50,736,733	Welltower, Inc.	8,784	710,538
Hewlett Packard Enterprise Co.	23,043	387,122	,		1,237,503
HP, Inc.	25,045 15,495	475,851			1,237,503
NetApp, Inc.	3,813	291,313	Hotel & Resort REITs 0.0%	40 700	
Seagate Technology Holdings	3,013	201,010	Host Hotels & Resorts, Inc.	12,762	214,785
PLC	3,388	209,616	Industrial REITs 0.3%		
Western Digital Corp.*	5,544	210,284	Prologis, Inc.	16,326	2,002,057
- ·		52,310,919	Office REITs 0.1%		
Materials 2.5%		02,010,010	Alexandria Real Estate		
			Equities, Inc.	2,772	314,594
Chemicals 1.7%			Boston Properties, Inc.	2,591	149,216
Air Products & Chemicals, Inc.	3,923	1,175,056			463,810
Albemarle Corp.	2,076	463,135	Real Estate Management &		
Celanese Corp.	1,753	202,997	Development 0.2%	E 400	440 =00
CF Industries Holdings, Inc.	3,449	239,430	CBRE Group, Inc. "A"*	5,496	443,582
Corteva, Inc.	12,644	724,501	CoStar Group, Inc.*	7,182	639,198
Dow, Inc.	12,436	662,341			1,082,780
DuPont de Nemours, Inc.	8,105	579,021	Residential REITs 0.3%		
Eastman Chemical Co.	2,127	178,073	AvalonBay Communities, Inc.	2,476	468,633
Ecolab, Inc.	4,398	821,063	Camden Property Trust	1,902	207,071

_	Shares	Value (\$)	_	Shares	Value (\$)
Equity Residential	6,090	401,757	Gas Utilities 0.0%		
Essex Property Trust, Inc.	1,134	265,696	Atmos Energy Corp.	2,572	299,227
Invitation Homes, Inc.	10,415	358,276	Independent Power & Renewak	·	,
Mid-America Apartment			Producers 0.0%	ne Electricity	
Communities, Inc.	2,090	317,387	AES Corp.	11,987	248,491
UDR, Inc.	5,380	231,125	·	,	,
		2,249,945	Multi-Utilities 0.7%	4 505	200 557
Retail REITs 0.3%			Ameren Corp.	4,525	369,557
Federal Realty Investment			CenterPoint Energy, Inc.	11,053	322,195
Trust	1,234	119,414	CMS Energy Corp.	5,092	299,155
Kimco Realty Corp.	11,100	218,892	Consolidated Edison, Inc.	6,107	552,073
Realty Income Corp.	11,853	708,691	Dominion Energy, Inc.	14,781	765,508
Regency Centers Corp.	2,740	169,250	DTE Energy Co.	3,611	397,282
Simon Property Group, Inc.	5,774	666,781	NiSource, Inc.	7,349	200,995
, , , , ,	_	1,883,028	Public Service Enterprise Group, Inc.	8,786	550,091
		1,003,020	•	5,581	
Specialized REITs 1.1%			Sempra Energy		812,538
American Tower Corp.	8,238	1,597,678	WEC Energy Group, Inc.	5,639	497,585
Crown Castle, Inc.	7,673	874,261			4,766,979
Digital Realty Trust, Inc.	5,149	586,317	Water Utilities 0.1%		
Equinix, Inc.	1,654	1,296,637	American Water Works		
Extra Space Storage, Inc.	2,398	356,942	Co., Inc.	3,452	492,773
Iron Mountain, Inc.	5,153	292,793	Total Common Stocks (Cost \$24	11 962 882)	657.468.505
Public Storage	2,803	818,140	iotai σοιιπιστί στοσκό (σοστ φ2-	1,002,002	007,400,000
SBA Communications Corp.	1,939	449,383		Principal	
VICI Properties, Inc.	17,703	556,405		Amount (\$)	Value (\$)
Weyerhaeuser Co.	12,900	432,279	Covernment & Agency		
		7,260,835	Government & Agency (Juligations	U. I /0
Utilities 2.5%			U.S. Treasury Obligations		
			U.S. Treasury Bills, 4.8% (a),		
Electric Utilities 1.7%	4.500	007.010	10/26/2023 (b) (Cost \$422,872)	430,000	422,857
Alliant Energy Corp.	4,520	237,210	(0031 \$422,072)	430,000	422,037
American Electric Power Co., Inc.	9,087	765,125		Shares	Value (\$)
Constellation Energy Corp.	5,744	525,863		Silares	value (\$)
Duke Energy Corp.	13,695	1,228,989	Cash Equivalents 0.8%		
Edison International	6,768	470,038	DWS Central Cash		
Entergy Corp.	3,711	361,340	Management Government Fund, 5.13% (c)		
Evergy, Inc.	4,030	235,433	(Cost \$5,529,637)	5,529,637	5,529,637
Eversource Energy	6,212	440,555	(0001 \$0,020,007)	0,020,007	0,020,007
Exelon Corp.	17,651	719,102		% of	
FirstEnergy Corp.	9,740	378,691		Net Assets	Value (\$)
NextEra Energy, Inc.	35,790	2,655,618			13332 (47
NRG Energy, Inc.	4,165	155,729	Total Investment Portfolio (Cost \$247,915,391)	100.0	663,420,999
PG&E Corp.*	28,862		Other Assets and	100.0	003,420,333
•	•	498,735	Liabilities, Net	0.0	168,267
Pinnacle West Capital Corp.	1,999	162,839			
PPL Corp.	12,915	341,731	Net Assets	100.0	663,589,266
Southern Co.	19,268	1,353,577			
Xcel Energy, Inc.	9,701	603,111			
		11,133,686			

A summary of the Fund's transactions with affiliated investments during the period ended June 30, 2023 are as follows:

Value (\$) at 12/31/2022	Purchases Cost (\$)	Sales Proceeds (\$)	Net Realized Gain/ (Loss) (\$)	Net Change in Unrealized Appreciation (Depreciation) (\$)	Income (\$)	Capital Gain Distributions (\$)	Number of Shares at 6/30/2023	Value (\$) at 6/30/2023
Securities Lending	g Collateral 0.09	%						
DWS Government	& Agency Securi	ities Portfolio "DW	/S Government (Cash Institutional S	hares", 5.03% (c)	(d)		
165,065	_	165,065 (e)	_	_	111	_	_	_
Cash Equivalents	0.8%							
DWS Central Cash	Management G	overnment Fund,	5.13% (c)					
1,297,774	46,413,683	42,181,820			100,094		5,529,637	5,529,637
1,462,839	46,413,683	42,346,885	_	_	100,205	_	5,529,637	5,529,637

- * Non-income producing security.
- (a) Annualized yield at time of purchase; not a coupon rate.
- (b) At June 30, 2023, this security has been pledged, in whole or in part, to cover initial margin requirements for open futures contracts.
- (c) Affiliated fund managed by DWS Investment Management Americas, Inc. The rate shown is the annualized seven-day yield at period end.
- (d) Represents cash collateral held in connection with securities lending. Income earned by the Fund is net of borrower rebates.
- (e) Represents the net increase (purchase cost) or decrease (sales proceeds) in the amount invested in cash collateral for the period ended June 30, 2023.

REIT: Real Estate Investment Trust

S&P: Standard & Poor's

At June 30, 2023, open futures contracts purchased were as follows:

Futures	Currency	Expiration Date	Contracts	Notional Amount (\$)	Notional Value (\$)	Unrealized Appreciation (\$)
S&P 500 E-Mini Index	USD	9/15/2023	27	5,966,730	6,059,138	92,408

Currency Abbreviation(s)

USD United States Dollar

For information on the Fund's policy and additional disclosures regarding futures contracts, please refer to the Derivatives section of Note B in the accompanying Notes to Financial Statements.

Fair Value Measurements

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.

The following is a summary of the inputs used as of June 30, 2023 in valuing the Fund's investments. For information on the Fund's policy regarding the valuation of investments, please refer to the Security Valuation section of Note A in the accompanying Notes to Financial Statements.

Assets	Level 1	Level 2	Level 3	Total	
Common Stocks (a)	\$ 657,468,505	\$ —	\$ —	\$ 657,468,505	
Government & Agency Obligations	_	422,857	_	422,857	
Short-Term Investments	5,529,637	_	_	5,529,637	
Derivatives (b) Futures Contracts	92,408	_	_	92,408	
Total	\$ 663,090,550	\$422,857	\$ —	\$ 663,513,407	

- (a) See Investment Portfolio for additional detailed categorizations.
- (b) Derivatives include unrealized appreciation (depreciation) on open futures contracts.

Statement of Assets and Liabilities

as of June 30, 2023 (Unaudited)

Investments in non-affiliated securities, at value		
(cost \$242,385,754)	\$	657,891,362
Investment in DWS Central Cash Management		F F00 00=
Government Fund (cost \$5,529,637)		5,529,637
Cash		3,765
Receivable for Fund shares sold		1,698
Dividends receivable		427,485
Interest receivable		25,212
Receivable for variation margin on futures contracts		92,501
Other assets		3,960
Total assets		663,975,620
Liabilities		,
Payable for Fund shares redeemed		151,665
Accrued management fee		77,188
Accrued Trustees' fees		2,395
Other accrued expenses and payables		155,106
Total liabilities		386,354
Net assets, at value	•	663,589,266
	_	000,000,200
Net Assets Consist of		
Distributable earnings (loss)		
Paid-in capital	¢	225,912,561
Paid-in capital Net assets, at value	\$	437,676,705 225,912,561 663,589,266
Paid-in capital Net assets, at value Net Asset Value	\$	225,912,561
Paid-in capital Net assets, at value Net Asset Value Class A	\$	225,912,561
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price	\$	225,912,561
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209	\$	225,912,561
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest,	\$	225,912,561
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price	\$	225,912,561 663,589,266
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of		225,912,561 663,589,266
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price	\$	225,912,561 663,589,26 6
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding	\$	225,912,561 663,589,26 6
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding shares of beneficial interest, \$.001 par value,	\$	225,912,561 663,589,266 24.99
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized)	\$	225,912,561 663,589,266 24.99
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B2	\$	225,912,56 663,589,266 24.95
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B2 Net Asset Value, offering and redemption price	\$	225,912,561 663,589,266 24.99
Paid-in capital Net assets, at value Net Asset Value Class A Net Asset Value, offering and redemption price per share (\$610,168,191 ÷ 24,414,209 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B Net Asset Value, offering and redemption price per share (\$50,783,832 ÷ 2,027,902 outstanding shares of beneficial interest, \$.001 par value, unlimited number of shares authorized) Class B2	\$	225,912,561 663,589,26 6

Statement of Operations

for the six months ended June 30, 2023 (Unaudited)

Investment Income	
Income:	
Dividends (net of foreign taxes withheld of \$1,429)	\$ 5,241,422
Interest	12,322
Income distributions — DWS Central Cash Management Government Fund	100,094
Securities lending income, net of borrower rebates	111
Total income	5,353,949
Expenses:	
Management fee	467,511
Administration fee	302,323
Services to shareholders	750
Record keeping fee (Class B and Class B-2)	37,711
Distribution service fees (Class B and Class B-2)	69,313
Custodian fee	5,853
Professional fees	36,286
Reports to shareholders	15,009
Trustees' fees and expenses	14,295
Other	22,170
Total expenses before expense reductions	971,221
Expense reductions	(49,505)
Total expenses after expense reductions	921,716
Net investment income	4,432,233
Realized and Unrealized Gain (Loss)	
Net realized gain (loss) from:	
Investments	24,524,009
Futures	862,077
	25,386,086
Change in net unrealized appreciation (depreciation) on:	
Investments	67,990,518
Futures	196,192
	68,186,710
Net gain (loss)	93,572,796
Net increase (decrease) in net assets resulting from operations	\$98,005,029

Statements of Changes in Net Assets

Increase (Decrease) in Net Assets	Six Months Ended Year Ende June 30, 2023 December (Unaudited) 2022	
Operations:		
Net investment income	\$ 4,432,233	\$ 8,542,532
Net realized gain (loss)	25,386,086	33,934,074
Change in net unrealized appreciation (depreciation)	68,186,710	(184,104,989)
Net increase (decrease) in net assets resulting from operations	98,005,029	(141,628,383)
Distributions to shareholders:		
Class A	(38,664,426)	(42,243,291)
Class B	(2,971,027)	(3,161,213)
Class B2	(159,941)	(1,142,904)
Total distributions	(41,795,394)	(46,547,408)
Fund share transactions:		
Class A		
Proceeds from shares sold	9,938,347	24,641,760
Reinvestment of distributions	38,664,426	42,243,291
Payments for shares redeemed	(33,557,663)	(71,401,621)
Net increase (decrease) in net assets from Class A share transactions	15,045,110	(4,516,570)
Class B Proceeds from shares sold	3,299,498	8,799,484
Reinvestment of distributions	2,971,027	3,161,213
Payments for shares redeemed	(3,042,169)	(10,018,364)
Net increase (decrease) in net assets from Class B share transactions	3,228,356	1,942,333
Class B2 Proceeds from shares sold	78,830	87,831
Reinvestment of distributions	159,941	1,142,904
Payments for shares redeemed	(13,920,355)	(1,749,644)
Net increase (decrease) in net assets from Class B2 share transactions	(13,681,584)	(518,909)
Increase (decrease) in net assets	60,801,517	(191,268,937)
Net assets at beginning of period	602,787,749	794,056,686
Net assets at end of period	\$663,589,266	\$ 602,787,749

Statements of Changes in Net Assets

Other Information	Six Months Ended June 30, 2023 (Unaudited)	Year Ended December 31, 2022
Class A	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Shares outstanding at beginning of period	23,699,901	23,787,108
Shares sold	417,712	992,800
Shares issued to shareholders in reinvestment of distributions	1,695,808	1,708,871
Shares redeemed	(1,399,212)	(2,788,878)
Net increase (decrease) in Class A shares	714,308	(87,207)
Shares outstanding at end of period	24,414,209	23,699,901
Class B		
Shares outstanding at beginning of period	1,885,936	1,814,686
Shares sold	138,179	344,087
Shares issued to shareholders in reinvestment of distributions	129,966	127,571
Shares redeemed	(126,179)	(400,408)
Net increase (decrease) in Class B shares	141,966	71,250
Shares outstanding at end of period	2,027,902	1,885,936
Class B2 Shares outstanding at beginning of period	655,653	676,257
Shares sold	3,281	3,714
Shares issued to shareholders in reinvestment of distributions	6,988	46,067
Shares redeemed	(560,731)	(70,385)
Net increase (decrease) in Class B2 shares	(550,462)	(20,604)
Shares outstanding at end of period	105,191	655,653

Financial Highlights

DWS Equity 500 Index VIP — Class A

	Six Months					
	Ended 6/30/23			ided Decei		
	(Unaudited)	2022	2021	2020	2019	2018
Selected Per Share Data						
Net asset value, beginning of period	\$22.97	\$30.22	\$24.97	\$23.14	\$18.90	\$22.19
Income (loss) from investment operations: Net investment income ^a	.17	.33	.31	.34	.35	.37
Net realized and unrealized gain (loss)	3.52	(5.75)	6.55	3.23	5.37	(1.31)
Total from investment operations	3.69	(5.42)	6.86	3.57	5.72	(.94)
Less distributions from: Net investment income	(.35)	(.32)	(.41)	(.39)	(.43)	(.38)
Net realized gains	(1.32)	(1.51)	(1.20)	(1.35)	(1.05)	(1.97)
Total distributions	(1.67)	(1.83)	(1.61)	(1.74)	(1.48)	(2.35)
Net asset value, end of period	\$24.99	\$22.97	\$30.22	\$24.97	\$23.14	\$18.90
Total Return (%) ^b	16.75*	(18.34)	28.40	18.10	31.19	(4.65)
Ratios to Average Net Assets and Supplemental Data						
Net assets, end of period (\$ millions)	610	544	719	607	561	472
Ratio of expenses before expense reductions (%)°	.28**	.32	.32	.33	.35	.34
Ratio of expenses after expense reductions (%)°	.26**	.26	.26	.26	.27	.30
Ratio of net investment income (%)	1.46**	1.33	1.14	1.56	1.68	1.73
Portfolio turnover rate (%)	1*	2	2	4	3	3

^a Based on average shares outstanding during the period.

b Total return would have been lower had certain expenses not been reduced.

^c Expense ratio does not reflect charges and fees associated with the separate account that invests in the Fund or any variable life insurance policy or variable annuity contract for which the Fund is an investment option.

^{*} Not annualized

^{**} Annualized

DWS Equity 500 Index VIP — Class B

	Six Months					
	Ended 6/30/23			ided Decei		
	(Unaudited)	2022	2021	2020	2019	2018
Selected Per Share Data						
Net asset value, beginning of period	\$22.97	\$30.20	\$24.95	\$23.12	\$18.89	\$22.17
Income (loss) from investment operations: Net investment income ^a	.13	.24	.21	.26	.28	.29
Net realized and unrealized gain (loss)	3.51	(5.74)	6.54	3.23	5.35	(1.29)
Total from investment operations	3.64	(5.50)	6.75	3.49	5.63	(1.00)
Less distributions from: Net investment income	(.25)	(.22)	(.30)	(.31)	(.35)	(.31)
Net realized gains	(1.32)	(1.51)	(1.20)	(1.35)	(1.05)	(1.97)
Total distributions	(1.57)	(1.73)	(1.50)	(1.66)	(1.40)	(2.28)
Net asset value, end of period	\$25.04	\$22.97	\$30.20	\$24.95	\$23.12	\$18.89
Total Return (%) ^b	16.51*	(18.62)	27.91	17.63	30.66	(4.94)
Ratios to Average Net Assets and Supplemental Data						
Net assets, end of period (\$ millions)	51	43	55	42	33	21
Ratio of expenses before expense reductions (%) ^c	.66**	.71	.71	.71	.72	.71
Ratio of expenses after expense reductions (%) ^c	.65**	.64	.64	.64	.65	.65
Ratio of net investment income (%)	1.07**	.95	.76	1.17	1.31	1.38
Portfolio turnover rate (%)	1*	2	2	4	3	3

^a Based on average shares outstanding during the period.

Total return would have been lower had certain expenses not been reduced.

Expense ratio does not reflect charges and fees associated with the separate account that invests in the Fund or any variable life insurance policy or variable annuity contract for which the Fund is an investment option.

^{*} Not annualized

^{**} Annualized

DWS Equity 500 Index VIP — Class B2

	Six Months					
	Ended 6/30/23			ided Decei		
	(Unaudited)	2022	2021	2020	2019	2018
Selected Per Share Data						
Net asset value, beginning of period	\$22.99	\$30.23	\$24.98	\$23.14	\$18.90	\$22.18
Income (loss) from investment operations: Net investment income ^a	.13	.23	.21	.25	.27	.28
Net realized and unrealized gain (loss)	3.52	(5.74)	6.54	3.24	5.36	(1.30)
Total from investment operations	3.65	(5.51)	6.75	3.49	5.63	(1.02)
Less distributions from: Net investment income	(.25)	(.22)	(.30)	(.30)	(.34)	(.29)
Net realized gains	(1.32)	(1.51)	(1.20)	(1.35)	(1.05)	(1.97)
Total distributions	(1.57)	(1.73)	(1.50)	(1.65)	(1.39)	(2.26)
Net asset value, end of period	\$25.07	\$22.99	\$30.23	\$24.98	\$23.14	\$18.90
Total Return (%) ^b	16.53*	(18.64)	27.86	17.64	30.64	(5.00)
Ratios to Average Net Assets and Supplemental Data						
Net assets, end of period (\$ millions)	3	15	20	18	17	15
Ratio of expenses before expense reductions (%)°	.67**	.71	.72	.72	.74	.73
Ratio of expenses after expense reductions (%)°	.65**	.65	.65	.65	.67	.70
Ratio of net investment income (%)	1.08**	.94	.75	1.17	1.28	1.32
Portfolio turnover rate (%)	1*	2	2	4	3	3

^a Based on average shares outstanding during the period.

Total return would have been lower had certain expenses not been reduced.

Expense ratio does not reflect charges and fees associated with the separate account that invests in the Fund or any variable life insurance policy or variable annuity contract for which the Fund is an investment option.

^{*} Not annualized

^{**} Annualized

Notes to Financial Statements

(Unaudited)

A. Organization and Significant Accounting Policies

Deutsche DWS Investments VIT Funds (the "Trust") is registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as an open-end management investment company. The Trust is organized as a Massachusetts business trust. DWS Equity 500 Index VIP (the "Fund") is a diversified series of the Trust offered to investors. The Fund is an underlying investment vehicle for variable annuity contracts and variable life insurance policies to be offered by the separate accounts of certain life insurance companies ("Participating Insurance Companies").

Multiple Classes of Shares of Beneficial Interest. The Fund offers three classes of shares (Class A shares, Class B shares and Class B2 shares). Class B and Class B2 shares are subject to Rule 12b-1 distribution fees under the 1940 Act and recordkeeping fees equal to an annual rate of up to 0.25% and of up to 0.15%, respectively, of the average daily net assets of the Class B and Class B2 shares of the Fund. Class A shares are not subject to such fees.

Investment income, realized and unrealized gains and losses, and certain fund-level expenses and expense reductions, if any, are borne pro rata on the basis of relative net assets by the holders of all classes of shares, except that each class bears certain expenses unique to that class (including the applicable 12b-1 distribution fees and recordkeeping fees). Differences in class-level expenses may result in payment of different per share dividends by class. All shares have equal rights with respect to voting subject to class-specific arrangements.

The Fund's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") which require the use of management estimates. Actual results could differ from those estimates. The Fund qualifies as an investment company under Topic 946 of Accounting Standards Codification of U.S. GAAP. The policies described below are followed consistently by the Fund in the preparation of its financial statements.

Security Valuation. Investments are stated at value determined as of the close of regular trading on the New York Stock Exchange on each day the exchange is open for trading.

The Fund's Board has designated DWS Investment Management Americas, Inc. (the "Advisor") as the valuation designee for the Fund pursuant to Rule 2a-5 under the 1940 Act. The Advisor's Pricing Committee (the "Pricing Committee") typically values securities using readily available market quotations or prices supplied by independent pricing services (which are considered fair values under Rule 2a-5). The Advisor has adopted fair valuation procedures that provide methodologies for fair valuing securities.

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.

Equity securities are valued at the most recent sale price or official closing price reported on the exchange (U.S. or foreign) or over-the-counter market on which they trade. Securities for which no sales are reported are valued at the calculated mean between the most recent bid and asked quotations on the relevant market or, if a mean cannot be determined, at the most recent bid quotation. Equity securities are generally categorized as Level 1.

Debt securities are valued at prices supplied by independent pricing services approved by the Pricing Committee. Such services may use various pricing techniques which take into account appropriate factors such as yield, quality, coupon rate, maturity, type of issue, trading characteristics, prepayment speeds and other data, as well as broker quotes. If the pricing services are unable to provide valuations, debt securities are valued at the average of the most recent reliable bid quotations or evaluated prices, as applicable, obtained from broker-dealers. These securities are generally categorized as Level 2.

Investments in open-end investment companies are valued at their net asset value each business day and are categorized as Level 1.

Futures contracts are generally valued at the settlement prices established each day on the exchange on which they are traded and are categorized as Level 1.

Securities and other assets for which market quotations are not readily available or for which the above valuation procedures are deemed not to reflect fair value are valued in a manner that is intended to reflect their fair value as determined in accordance with procedures approved by the Pricing Committee and are generally categorized as Level 3. In accordance with the Fund's valuation procedures, factors considered in determining value may include, but are not limited to, the type of the security; the size of the holding; the initial cost of the security; the existence of any contractual restrictions on the security's disposition; the price and extent of public trading in similar securities of the issuer or of comparable companies; quotations or evaluated prices from broker-dealers and/or pricing services; information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded securities); an analysis of the company's or issuer's financial statements; an evaluation of the forces that influence the issuer and the market(s) in which the security is purchased and sold; and with respect to debt securities, the maturity, coupon, creditworthiness, currency denomination and the movement of the market in which the security is normally traded. The value determined under these procedures may differ from published values for the same securities.

Disclosure about the classification of fair value measurements is included in a table following the Fund's Investment Portfolio.

Securities Lending. Deutsche Bank AG, as securities lending agent, lends securities of the Fund to certain financial institutions under the terms of its securities lending agreement. During the term of the loans, the Fund continues to receive interest and dividends generated by the securities and to participate in any changes in their market value. The Fund requires the borrowers of the securities to maintain collateral with the Fund consisting of either cash or liquid, unencumbered assets having a value at least equal to the value of the securities loaned. When the collateral falls below specified amounts, the securities lending agent will use its best efforts to obtain additional collateral on the next business day to meet required amounts under the securities lending agreement. As of period end, any securities on loan were collateralized by cash. During the six months ended June 30, 2023, the Fund invested the cash collateral into a joint trading account in DWS Government & Agency Securities Portfolio, an affiliated money market fund managed by DWS Investment Management Americas, Inc. DWS Investment Management Americas, Inc. receives a management/administration fee (0.07% annualized effective rate as of June 30, 2023) on the cash collateral invested in DWS Government & Agency Securities Portfolio. The Fund receives compensation for lending its securities either in the form of fees or by earning interest on invested cash collateral net of borrower rebates and fees paid to a securities lending agent. Either the Fund or the borrower may terminate the loan at any time, and the borrower, after notice, is required to return borrowed securities within a standard time period. There may be risks of delay and costs in recovery of securities or even loss of rights in the collateral should the borrower of the securities fail financially. If the Fund is not able to recover securities lent, the Fund may sell the collateral and purchase a replacement investment in the market, incurring the risk that the value of the replacement security is greater than the value of the collateral. The Fund is also subject to all investment risks associated with the reinvestment of any cash collateral received, including, but not limited to, interest rate, credit and liquidity risk associated with such investments.

As of June 30, 2023, the Fund had no securities on loan.

Federal Income Taxes. The Fund is treated as a separate taxpayer as provided for in the Internal Revenue Code of 1986, as amended (the "Code"). It is the Fund's policy to comply with the requirements of the Code, which are applicable to regulated investment companies, and to distribute all of its taxable income to the separate accounts of the Participating Insurance Companies which hold its shares.

At June 30, 2023, the aggregate cost of investments for federal income tax purposes was \$255,681,571. The net unrealized appreciation for all investments based on tax cost was \$407,739,428. This consisted of aggregate gross unrealized appreciation for all investments for which there was an excess of value over tax cost of \$427,079,965 and aggregate gross unrealized depreciation for all investments for which there was an excess of tax cost over value of \$19,340,537.

The Fund has reviewed the tax positions for the open tax years as of December 31, 2022 and has determined that no provision for income tax and/or uncertain tax positions is required in the Fund's financial statements. The Fund's federal tax returns for the prior three fiscal years remain open subject to examination by the Internal Revenue Service.

Distribution of Income and Gains. Distributions from net investment income of the Fund, if any, are declared and distributed to shareholders annually. Net realized gains from investment transactions, in excess of

available capital loss carryforwards, would be taxable to the Fund if not distributed, and, therefore, will be distributed to shareholders at least annually. The Fund may also make additional distributions for tax purposes if necessary.

The timing and characterization of certain income and capital gain distributions are determined annually in accordance with federal tax regulations which may differ from accounting principles generally accepted in the United States of America. These differences primarily relate to certain securities sold at a loss, investments in derivatives, the realized tax character on distributions from certain securities and income related to restructuring of certain securities. As a result, net investment income (loss) and net realized gain (loss) on investment transactions for a reporting period may differ significantly from distributions during such period. Accordingly, the Fund may periodically make reclassifications among certain of its capital accounts without impacting the net asset value of the Fund.

The tax character of current year distributions will be determined at the end of the current fiscal year.

Contingencies. In the normal course of business, the Fund may enter into contracts with service providers that contain general indemnification clauses. The Fund's maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Fund that have not yet been made. However, based on experience, the Fund expects the risk of loss to be remote.

Expenses. Expenses of the Trust arising in connection with a specific fund are allocated to that fund. Other Trust expenses which cannot be directly attributed to a fund are apportioned among the funds in the Trust based upon the relative net assets or other appropriate measures.

Real Estate Investment Trusts. The Fund at its fiscal year end recharacterizes distributions received from a Real Estate Investment Trust ("REIT") investment based on information provided by the REIT into the following categories: ordinary income, long-term and short-term capital gains, and return of capital. If information is not available timely from a REIT, the recharacterization will be estimated for financial reporting purposes and a recharacterization will be made to the accounting records in the following year when such information becomes available. Distributions received from REITs in excess of income are recorded as either a reduction of cost of investments or realized gains.

Other. Investment transactions are accounted for on a trade date plus one basis for daily net asset value calculations. However, for financial reporting purposes, investment transactions are reported on trade date. Interest income is recorded on the accrual basis. Dividend income is recorded on the ex-dividend date. Realized gains and losses from investment transactions are recorded on an identified cost basis. Proceeds from litigation payments, if any, are included in net realized gain (loss) from investments.

B. Derivative Instruments

A futures contract is an agreement between a buyer or seller and an established futures exchange or its clearinghouse in which the buyer or seller agrees to take or make a delivery of a specific amount of a financial instrument at a specified price on a specific date (settlement date). For the six months ended June 30, 2023, the Fund invested in futures to keep cash on hand to meet shareholder redemptions or other needs while maintaining exposure to the stock market.

Upon entering into a futures contract, the Fund is required to deposit with a financial intermediary cash or securities ("initial margin") in an amount equal to a certain percentage of the face value indicated in the futures contract. Subsequent payments ("variation margin") are made or received by the Fund dependent upon the daily fluctuations in the value and are recorded for financial reporting purposes as unrealized gains or losses by the Fund. Gains or losses are realized when the contract expires or is closed. Since all futures contracts are exchange-traded, counterparty risk is minimized as the exchange's clearinghouse acts as the counterparty, and guarantees the futures against default. Upon a futures contract close out or expiration, realized gain or loss is recognized.

Certain risks may arise upon entering into futures contracts, including the risk that an illiquid market will limit the Fund's ability to close out a futures contract prior to the settlement date and the risk that the futures contract is not well correlated with the security, index or currency to which it relates. Risk of loss may exceed amounts recognized in the Statement of Assets and Liabilities.

A summary of the open futures contracts as of June 30, 2023, is included in a table following the Fund's Investment Portfolio. For the six months ended June 30, 2023, the investment in futures contracts purchased had a total notional value generally indicative of a range from approximately \$2,703,000 to \$9,724,000.

The following table summarizes the value of the Fund's derivative instruments held as of June 30, 2023 and the related location in the accompanying Statement of Assets and Liabilities, presented by primary underlying risk exposure:

Assets Derivative	Futures Contracts
Equity Contracts (a)	\$ 92,408

The above derivative is located in the following Statement of Assets and Liabilities account:

(a) Includes cumulative appreciation of futures contracts as disclosed in the Investment Portfolio. Unsettled variation margin is disclosed separately within the Statement of Assets and Liabilities.

Additionally, the amount of unrealized and realized gains and losses on derivative instruments recognized in Fund earnings during the six months ended June 30, 2023 and the related location in the accompanying Statement of Operations is summarized in the following tables by primary underlying risk exposure:

Realized Gain (Loss)	Contracts
Equity Contracts (a)	\$ 862,077
The above derivative is located in the following Statement of Operations account:	

Futures

(a) Net realized gain (loss) from futures contracts

Change in Net Unrealized Appreciation (Depreciation)	Contracts
Equity Contracts (a)	\$ 196,192

The above derivative is located in the following Statement of Operations account:

(a) Change in net unrealized appreciation (depreciation) on futures contracts

C. Purchases and Sales of Securities

During the six months ended June 30, 2023, purchases and sales of investment securities (excluding short-term investments) aggregated \$3,225,332 and \$38,642,536, respectively.

D. Related Parties

Management Agreement. Under the Investment Management Agreement with DWS Investment Management Americas, Inc. ("DIMA" or the "Advisor"), an indirect, wholly owned subsidiary of DWS Group GmbH & Co. KGaA ("DWS Group"), the Advisor determines the securities, instruments and other contracts relating to investments to be purchased, sold or entered into by the Fund or delegates such responsibility to the Fund's subadvisor. Northern Trust Investments, Inc. ("NTI") serves as subadvisor. As a subadvisor to the Fund, NTI makes investment decisions and buys and sells securities for the Fund. NTI is paid by the Advisor for the services NTI provides to the Fund.

Under the Investment Management Agreement with the Advisor, the Fund pays the Advisor an annual fee based on the average daily net assets of the Fund, computed and accrued daily and payable monthly, at the following annual rates:

First \$1 billion of the Fund's average daily net assets	.150%
Next \$1 billion of such net assets	.125%
Over \$2 billion of such net assets	.100%

Accordingly, for the six months ended June 30, 2023, the fee pursuant to the Investment Management Agreement was equivalent to an annualized rate (exclusive of any applicable waivers/reimbursements) of 0.15% of the Fund's average daily net assets.

For the period from January 1, 2023 through April 30, 2024 (through April 30, 2023 for Class B shares), the Advisor has contractually agreed to waive its fees and/or reimburse certain operating expenses of the Fund to the extent necessary to maintain the total annual operating expenses (excluding certain expenses such as

extraordinary expenses, taxes, brokerage, interest expense and acquired fund fees and expenses) of each class as follows:

Class A	.26%
Class B	.64%
Class B2	.65%

Effective May 1, 2023 through April 30, 2024, the Advisor has contractually agreed to waive its fees and/or reimburse certain operating expenses of Class B shares to the extent necessary to maintain the total annual operating expenses (excluding certain expenses such as extraordinary expenses, taxes, brokerage, interest expense and acquired fund fees and expenses) at 0.65%.

For the six months ended June 30, 2023, fees waived and/or expenses reimbursed for each class are as follows:

	\$ 49,505
Class B2	1,003
Class B	3,945
Class A	\$ 44,557

Administration Fee. Pursuant to an Administrative Services Agreement, DIMA provides most administrative services to the Fund. For all services provided under the Administrative Services Agreement, the Fund pays the Advisor an annual fee ("Administration Fee") of 0.097% of the Fund's average daily net assets, computed and accrued daily and payable monthly. For the six months ended June 30, 2023, the Administration Fee was \$302,323, of which \$51,812 is unpaid.

Distribution Service Agreement. DWS Distributors, Inc. ("DDI"), an affiliate of the Advisor, is the Fund's distributor. In accordance with the Distribution Plan, DDI receives 12b-1 fees of up to 0.25% of the average daily net assets of Class B and B2 shares. For the six months ended June 30, 2023, the Distribution Service Fees were as follows:

Distribution Service Fees	Total Aggregated	Unpaid at June 30, 2023
Class B	\$ 57,323	\$ 10,201
Class B2	11,990	529
	\$ 69,313	\$ 10,730

Service Provider Fees. DWS Service Company ("DSC"), an affiliate of the Advisor, is the transfer agent, dividend-paying agent and shareholder service agent for the Fund. Pursuant to a sub-transfer agency agreement between DSC and SS&C GIDS, Inc. ("SS&C") (name changed from DST Systems, Inc. effective January 1, 2023), DSC has delegated certain transfer agent, dividend-paying agent and shareholder service agent functions to SS&C. DSC compensates SS&C out of the shareholder servicing fee it receives from the Fund. For the six months ended June 30, 2023, the amounts charged to the Fund by DSC were as follows:

Services to Shareholders	Total Aggregated	Unpaid at June 30, 2023
Class A	\$ 313	\$ 103
Class B	60	15
Class B2	37	11
	\$ 410	\$ 129

Other Service Fees. Under an agreement with the Fund, DIMA is compensated for providing regulatory filing services to the Fund. For the six months ended June 30, 2023, the amount charged to the Fund by DIMA included in the Statement of Operations under "Reports to shareholders" aggregated \$3,063, of which \$170 is unpaid.

Trustees' Fees and Expenses. The Fund paid retainer fees to each Trustee not affiliated with the Advisor, plus specified amounts to the Board Chairperson and to each committee Chairperson.

Affiliated Cash Management Vehicles. The Fund may invest uninvested cash balances in DWS Central Cash Management Government Fund and DWS ESG Liquidity Fund, affiliated money market funds which are managed by the Advisor. Each affiliated money market fund is managed in accordance with Rule 2a-7 under the 1940 Act, which governs the quality, maturity, diversity and liquidity of instruments in which a money market fund may invest. DWS Central Cash Management Government Fund seeks to maintain a stable net asset value, and DWS ESG Liquidity Fund maintains a floating net asset value. The Fund indirectly bears its proportionate share of the expenses of each affiliated money market fund in which it invests. DWS Central Cash Management Government Fund does not pay the Advisor an investment management fee. To the extent that DWS ESG Liquidity Fund pays an investment management fee to the Advisor, the Advisor will waive an amount of the investment management fee payable to the Advisor by the Fund equal to the amount of the investment management fee payable on the Fund's assets invested in DWS ESG Liquidity Fund.

Securities Lending Agent Fees. Deutsche Bank AG serves as securities lending agent for the Fund. For the six months ended June 30, 2023, the Fund incurred securities lending agent fees to Deutsche Bank AG in the amount of \$9.

E. Ownership of the Fund

At June 30, 2023, two participating insurance companies were owners of record of 10% or more of the total outstanding Class A shares of the Fund, each owning 50% and 15%, respectively. One participating insurance company was owner of record of 10% or more of the total outstanding Class B shares of the Fund, owning 90%. One participating insurance company was owner of record of 10% or more of the total outstanding Class B2 shares of the Fund, owning 100%.

F. Line of Credit

The Fund and other affiliated funds (the "Participants") share in a \$375 million revolving credit facility provided by a syndication of banks. The Fund may borrow for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. The Participants are charged an annual commitment fee, which is allocated based on net assets, among each of the Participants. Interest is calculated at a daily fluctuating rate per annum equal to the sum of 0.10% plus the higher of the Federal Funds Effective Rate and the Overnight Bank Funding Rate, plus 1.25%. The Fund may borrow up to a maximum of 33 percent of its net assets under the agreement. The Fund had no outstanding loans at June 30, 2023.

Other Information (Unaudited)

Regulatory Update — Tailored Shareholder Report

Effective January 24, 2023, the SEC amended the rules for mutual fund and exchange-traded fund ("ETF") annual and semi-annual shareholder reports. The amended rules apply to mutual funds and ETFs that are registered on Form N-1A (i.e., open-end funds) and implement a new streamlined disclosure framework requiring "concise and visually engaging" shareholder reports highlighting key information, including a simplified expense presentation, performance information, portfolio holdings and certain fund statistics. The amended rules seek to simplify shareholder reporting by consolidating investor friendly data in one report and moving other data to Form N-CSR, creating a layered disclosure framework. Certain information from the Fund's current shareholder reports, including the Fund's investment portfolio, financial statements and financial highlights, will move to Form N-CSR. This information must be available online, delivered free of charge upon request and filed on a semiannual basis on Form N-CSR. Notably, the amended rules will require mutual funds and ETFs to prepare separate individual shareholder reports for each fund share class. The amendments also include a revised definition of "appropriate broad-based securities market index" that will affect performance presentations in the new streamlined reports and mutual fund and ETF prospectuses. The amended rules and related form amendments have a compliance date of July 24, 2024. At this time, management is evaluating the impact of the amended rules and form amendments on the content of the Fund's current shareholder reports.

Information About Your Fund's Expenses

(Unaudited)

As an investor of the Fund, you incur two types of costs: ongoing expenses and transaction costs. Ongoing expenses include management fees, distribution and service (12b-1) fees and other Fund expenses. Examples of transaction costs include contract charges, which are not shown in this section. The following tables are intended to help you understand your ongoing expenses (in dollars) of investing in the Fund and to help you compare these expenses with the ongoing expenses of investing in other mutual funds. In the most recent six-month period, the Fund limited these expenses; had it not done so, expenses would have been higher. The example in the table is based on an investment of \$1,000 invested at the beginning of the six-month period and held for the entire period (January 1, 2023 to June 30, 2023).

The tables illustrate your Fund's expenses in two ways:

- **Actual Fund Return**. This helps you estimate the actual dollar amount of ongoing expenses (but not transaction costs) paid on a \$1,000 investment in the Fund using the Fund's actual return during the period. To estimate the expenses you paid over the period, simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the "Expenses Paid per \$1,000" line under the share class you hold.
- Hypothetical 5% Fund Return. This helps you to compare your Fund's ongoing expenses (but not transaction costs) with those of other mutual funds using the Fund's actual expense ratio and a hypothetical rate of return of 5% per year before expenses. Examples using a 5% hypothetical fund return may be found in the shareholder reports of other mutual funds. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period.

Please note that the expenses shown in these tables are meant to highlight your ongoing expenses only and do not reflect any transaction costs. The "Expenses Paid per \$1,000" line of the tables is useful in comparing ongoing expenses only and will not help you determine the relative total expense of owning different funds. If these transaction costs had been included, your costs would have been higher.

Expenses and Value of a \$1,000 Investment for the six months ended June 30, 2023

•				
Actual Fund Return	С	lass A	Class B	Class B2
Beginning Account Value 1/1/23	\$ 1,0	00.00	\$ 1,000.00	\$ 1,000.00
Ending Account Value 6/30/23	\$ 1,1	67.50	\$ 1,165.10	\$ 1,165.30
Expenses Paid per \$1,000*	\$	1.40	\$ 3.49	\$ 3.49
Hypothetical 5% Fund Return	С	lass A	Class B	Class B2
Beginning Account Value 1/1/23	\$ 1,0	00.00	\$ 1,000.00	\$ 1,000.00
Ending Account Value 6/30/23	\$ 1,0	23.51	\$ 1,021.57	\$ 1,021.57
Expenses Paid per \$1,000*	\$	1.30	\$ 3.26	\$ 3.26

^{*} Expenses are equal to the Fund's annualized expense ratio for each share class, multiplied by the average account value over the period, multiplied by 181 (the number of days in the most recent six-month period), then divided by 365.

Annualized Expense Ratios	Class A	Class B	Class B2
DWS Equity 500 Index VIP	.26%	.65%	.65%

For more information, please refer to the Fund's prospectus.

These tables do not reflect charges and fees ("contract charges") associated with the separate account that invests in the Fund or any variable life insurance policy or variable annuity contract for which the Fund is an investment option.

For an analysis of the fees associated with an investment in the Fund or similar funds, please refer to the current and hypothetical expense calculators for Variable Insurance Products which can be found at dws.com/calculators.

Liquidity Risk Management

In accordance with Rule 22e-4 (the "Liquidity Rule") under the Investment Company Act of 1940 (the "1940 Act"), your Fund has adopted a liquidity risk management program (the "Program"), and the Board has designated DWS Investment Management Americas, Inc. ("DIMA") as Program administrator. The Program is designed to assess and manage your Fund's liquidity risk (the risk that the Fund would be unable to meet requests to redeem shares of the Fund without significant dilution of remaining investors' interests in the Fund). DIMA has designated a committee (the "Committee") composed of personnel from multiple departments within DIMA and its affiliates that is responsible for the implementation and ongoing administration of the Program, which includes assessing the Fund's liquidity risk under both normal and reasonably foreseeable stressed conditions. Under the Program, every investment held by the Fund is classified on a daily basis into one of four liquidity categories based on estimations of the investment's ability to be sold during designated timeframes in current market conditions without significantly changing the investment's market value.

In February 2023, as required by the Program and the Liquidity Rule, DIMA provided the Board with an annual written report (the "Report") addressing the operation of the Program and assessing the adequacy and effectiveness of its implementation during the period from December 1, 2021 through November 30, 2022 (the "Reporting Period"). During the Reporting Period, your Fund was predominately invested in highly liquid investments (investments that the Fund anticipates can be converted to cash within three business days or less in current market conditions without significantly changing their market value). As a result, your Fund is not required to adopt, and has not adopted, a "Highly Liquid Investment Minimum" as defined in the Liquidity Rule. During the Reporting Period, the Fund did not approach the 15% limit imposed by the Liquidity Rule on holdings in illiquid investments (investments that cannot be sold or disposed of in seven days or less in current market conditions without the sale of the investment significantly changing the market value of the investment). Your Fund did not experience any issues meeting investor redemptions at any time during the Reporting Period. In the Report, DIMA stated that it believes the Program has operated adequately and effectively to manage the Fund's liquidity risk during the Reporting Period. DIMA also reported that there were no material changes made to the Program during the Reporting Period.

Proxy Voting

The Trust's policies and procedures for voting proxies for portfolio securities and information about how the Trust voted proxies related to its portfolio securities during the most recent 12-month period ended June 30 are available on our Web site — dws.com/en-us/resources/proxy-voting — or on the SEC's Web site — sec.gov. To obtain a written copy of the Trust's policies and procedures without charge, upon request, call us toll free at (800) 728-3337.

Advisory Agreement Board Considerations and Fee Evaluation

The Board of Trustees (hereinafter referred to as the "Board" or "Trustees") approved the renewal of DWS Equity 500 Index VIP's (the "Fund") investment management agreement (the "Agreement") with DWS Investment Management Americas, Inc. ("DIMA") and sub-advisory agreement (the "Sub-Advisory Agreement" and together with the Agreement, the "Agreements") between DIMA and Northern Trust Investments, Inc. ("NTI") in September 2022.

In terms of the process that the Board followed prior to approving the Agreements, shareholders should know that:

- During the entire process, all of the Fund's Trustees were independent of DIMA and its affiliates (the "Independent Trustees").
- The Board met frequently during the past year to discuss fund matters and dedicated a substantial amount of time to contract review matters. Over the course of several months, the Board reviewed extensive materials received from DIMA, independent third parties and independent counsel. These materials included an analysis of the Fund's performance, fees and expenses, and profitability from a fee consultant retained by the Fund's Independent Trustees (the "Fee Consultant").
- The Board also received extensive information throughout the year regarding performance of the Fund.
- The Independent Trustees regularly met privately with counsel to discuss contract review and other matters. In addition, the Independent Trustees were advised by the Fee Consultant in the course of their review of the Fund's contractual arrangements and considered a comprehensive report prepared by the Fee Consultant in connection with their deliberations.
- In connection with reviewing the Agreements, the Board also reviewed the terms of the Fund's Rule 12b-1 plan, distribution agreement, administrative services agreement, transfer agency agreement and other material service agreements.

In connection with the contract review process, the Board considered the factors discussed below, among others. The Board also considered that DIMA and its predecessors have managed the Fund since its inception, and the Board believes that a long-term relationship with a capable, conscientious advisor is in the best interests of the Fund. The Board considered, generally, that shareholders chose to invest or remain invested in the Fund knowing that DIMA managed the Fund. DIMA is part of DWS Group GmbH & Co. KGaA ("DWS Group"). DWS Group is a global asset management business that offers a wide range of investing expertise and resources, including research capabilities in many countries throughout the world. In 2018, approximately 20% of DWS Group's shares were sold in an initial public offering, with Deutsche Bank AG owning the remaining shares.

As part of the contract review process, the Board carefully considered the fees and expenses of each DWS fund overseen by the Board in light of the fund's performance. In many cases, this led to the negotiation and implementation of expense caps.

While shareholders may focus primarily on fund performance and fees, the Fund's Board considers these and many other factors, including the quality and integrity of DIMA's and NTI's personnel and administrative support services provided by DIMA, such as back-office operations, fund valuations, and compliance policies and procedures.

Nature, Quality and Extent of Services. The Board considered the terms of the Agreements, including the scope of advisory services provided under the Agreements. The Board noted that, under the Agreements, DIMA and NTI provide portfolio management services to the Fund and that, pursuant to a separate administrative services agreement, DIMA provides administrative services to the Fund. The Board considered the experience and skills of senior management and investment personnel and the resources made available to such personnel. The Board also considered the risks to DIMA in sponsoring or managing the Fund, including financial, operational and reputational risks, the potential economic impact to DIMA from such risks and DIMA's approach to addressing such risks. Throughout the course of the year, the Board also received information regarding DIMA's oversight of fund sub-advisors, including NTI. The Board reviewed the Fund's performance over short-term and long-term periods and compared those returns to various agreedupon performance measures, including market index(es) and a peer universe compiled using information supplied by Morningstar Direct ("Morningstar"), an independent fund data service. The Board also noted that it has put into place a process of identifying "Funds in Review" (e.g., funds performing poorly relative to a peer universe), and receives additional reporting from DIMA regarding such funds and, where appropriate, DIMA's plans to address underperformance. The Board believes this process is an effective manner of identifying and addressing underperforming funds. Based on the information provided, the Board noted that,

for the one-, three- and five-year periods ended December 31, 2021, the Fund's performance (Class A shares) was in the 2nd quartile, 2nd quartile and 1st quartile, respectively, of the applicable Morningstar universe (the 1st quartile being the best performers and the 4th quartile being the worst performers).

Fees and Expenses. The Board considered the Fund's investment management fee schedule, sub-advisory fee schedule, operating expenses and total expense ratios, and comparative information provided by Broadridge Financial Solutions, Inc. ("Broadridge") and the Fee Consultant regarding investment management fee rates paid to other investment advisors by similar funds (1st quartile being the most favorable and 4th quartile being the least favorable). With respect to management fees paid to other investment advisors by similar funds, the Board noted that the contractual fee rates paid by the Fund, which include a 0.097% fee paid to DIMA under the Fund's administrative services agreement, were higher than the median (4th quartile) of the applicable Broadridge peer group (based on Broadridge data provided as of December 31, 2021). The Board noted that, effective October 1, 2022, in connection with the 2022 contract renewal process, DIMA agreed to reduce the Fund's contractual management fee at each breakpoint by 0.05%. With respect to the sub-advisory fee paid to NTI, the Board noted that the fee is paid by DIMA out of its fee and not directly by the Fund. The Board noted that the Fund's Class A shares total (net) operating expenses were expected to be higher than the median (3rd quartile) of the applicable Broadridge expense universe (based on Broadridge data provided as of December 31, 2021, and analyzing Broadridge expense universe Class A (net) expenses less any applicable 12b-1 fees) ("Broadridge Universe Expenses"). The Board also reviewed data comparing each other operational share class's total (net) operating expenses to the applicable Broadridge Universe Expenses. The Board noted that the expense limitations agreed to by DIMA were expected to help the Fund's total (net) operating expenses remain competitive. The Board considered the Fund's management fee rate as compared to fees charged by DIMA to comparable DWS U.S. registered funds ("DWS Funds") and considered differences between the Fund and the comparable DWS Funds. The information requested by the Board as part of its review of fees and expenses also included information about institutional accounts (including any sub-advised funds and accounts) and funds offered primarily to European investors ("DWS Europe Funds") managed by DWS Group. The Board noted that DIMA indicated that DWS Group does not manage any institutional accounts or DWS Europe Funds comparable to the Fund.

On the basis of the information provided, the Board concluded that management fees were reasonable and appropriate in light of the nature, quality and extent of services provided by DIMA and NTI.

Profitability. The Board reviewed detailed information regarding revenues received by DIMA under the Agreement. The Board considered the estimated costs to DIMA, and pre-tax profits realized by DIMA, from advising the DWS Funds, as well as estimates of the pre-tax profits attributable to managing the Fund in particular. The Board also received information regarding the estimated enterprise-wide profitability of DIMA and its affiliates with respect to all fund services in totality and by fund. The Board and the Fee Consultant reviewed DIMA's methodology in allocating its costs to the management of the Fund. Based on the information provided, the Board concluded that the pre-tax profits realized by DIMA in connection with the management of the Fund were not unreasonable. The Board also reviewed certain publicly available information regarding the profitability of certain similar investment management firms. The Board noted that, while information regarding the profitability of such firms is limited (and in some cases is not necessarily prepared on a comparable basis), DIMA and its affiliates' overall profitability with respect to the DWS Funds (after taking into account distribution and other services provided to the funds by DIMA and its affiliates) was lower than the overall profitability levels of most comparable firms for which such data was available. The Board did not consider the profitability of NTI with respect to the Fund. The Board noted that DIMA pays NTI's fee out of its management fee, and its understanding that the Fund's sub-advisory fee schedule was the product of an arm's length negotiation with DIMA.

Economies of Scale. The Board considered whether there are economies of scale with respect to the management of the Fund and whether the Fund benefits from any economies of scale. The Board noted that the Fund's investment management fee schedule includes fee breakpoints. The Board concluded that the Fund's fee schedule represents an appropriate sharing between the Fund and DIMA of such economies of scale as may exist in the management of the Fund at current asset levels.

Other Benefits to DIMA and NTI and Their Affiliates. The Board also considered the character and amount of other incidental or "fall-out" benefits received by DIMA and NTI and their affiliates, including any fees received by DIMA for administrative services provided to the Fund, any fees received by an affiliate of DIMA for transfer agency services provided to the Fund and any fees received by an affiliate of DIMA for distribution services. The Board also considered benefits to DIMA related to brokerage and soft-dollar allocations, including allocating brokerage to pay for research generated by parties other than the executing

broker dealers, which pertain primarily to funds investing in equity securities. In addition, the Board considered the incidental public relations benefits to DIMA related to DWS Funds advertising and cross-selling opportunities among DIMA products and services. The Board considered these benefits in reaching its conclusion that the Fund's management fees were reasonable.

Compliance. The Board considered the significant attention and resources dedicated by DIMA to its compliance processes in recent years. The Board noted in particular (i) the experience, seniority and time commitment of the individuals serving as DIMA's and the Fund's chief compliance officers and (ii) the substantial commitment of resources by DIMA and its affiliates to compliance matters, including the retention of compliance personnel. The Board also considered the attention and resources dedicated by DIMA to the oversight of the investment sub-advisor's compliance program and compliance with the applicable fund policies and procedures.

Based on all of the information considered and the conclusions reached, the Board determined that the continuation of the Agreements is in the best interests of the Fund. In making this determination, the Board did not give particular weight to any single factor identified above. The Board considered these factors over the course of numerous meetings, certain of which were in executive session with only the Independent Trustees and counsel present. It is possible that individual Independent Trustees may have weighed these factors differently in reaching their individual decisions to approve the continuation of the Agreements.

Notes

